Logo image
Back
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Journal article   Peer reviewed

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Cecilia G Carvalhaes, Leonard R Duncan, Wen Wang and Helio S Sader
Antimicrobial agents and chemotherapy, Vol.64(11), e01195-20
10/20/2020
DOI: 10.1128/AAC.01195-20
PMID: 32778552
url
https://www.ncbi.nlm.nih.gov/pmc/articles/7577137View
Open Access

Abstract

Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates ( n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC 50/90 , 0.5/1 mg/liter), coagulase-negative Staphylococcus (MIC 50/90 , 0.25/0.5 mg/liter), Enterococcus spp. ABSTRACT Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates ( n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC 50/90 , 0.5/1 mg/liter), coagulase-negative Staphylococcus (MIC 50/90 , 0.25/0.5 mg/liter), Enterococcus spp. (MIC 50/90 , 0.5/1 mg/liter), and streptococci (MIC 50/90 , 1/1 mg/liter). Moreover, methicillin-resistant S. aureus and vancomycin-resistant Enterococcus faecium isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.

Details

Metrics

18 Record Views
34 Times Cited - Web of Science
Logo image